<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Surgical management of primary cutaneous melanoma or melanoma at other unusual sites</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Surgical management of primary cutaneous melanoma or melanoma at other unusual sites</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Surgical management of primary cutaneous melanoma or melanoma at other unusual sites</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey E Gershenwald, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily Keung, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin Weiser, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell S Berman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Melanomas most frequently occur in sun-exposed areas of the skin (ie, cutaneous melanoma of the trunk, extremities, head, and neck) but may arise in number of other sites such as the nail bed, palms, or soles (eg, acral lentiginous melanoma), on the external genitalia, in mucous membranes (mucosal melanoma), or in the eye (uveal or conjunctival melanoma). </p><p>The surgical principles for managing primary cutaneous melanoma presenting in the head, neck, trunk, and extremities are reviewed. The management of more unusual sites, including mucosal and uveal, are briefly discussed and reviewed more fully in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/16904.html" rel="external">"Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas"</a>.)</p><p class="headingAnchor" id="H1368947191"><span class="h1">ROLE OF SURGERY</span><span class="headingEndMark"> — </span>Proper surgical management is critical for the diagnosis, staging, and optimal treatment of primary cutaneous melanoma.</p><p>The goals of surgery include:</p><p class="bulletIndent1"><span class="glyph">●</span>Histologic confirmation of the diagnosis, which ideally had been established prior to definitive surgical management through an appropriately planned biopsy. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Diagnosis confirmation'</a> and  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtaining complete and accurate pathologic staging of the primary tumor (and when appropriate, regional nodal basin staging by sentinel lymph node biopsy [SLNB]) to guide further treatment and management at the same operative setting as wide excision of the primary melanoma. (See  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wide excision of the primary melanoma site with an appropriate margin of normal tissue around the primary site to minimize the risk of local recurrence. (See <a class="local">'Resection margins'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wide excision of the primary site with optimal functional and cosmetic outcomes.</p><p></p><p>Surgery is also an important component in the management of other aspects of melanoma staging and treatment. These issues, including regional nodal basin staging by SLNB at the same operative setting as wide excision of the primary melanoma, are the subject of other topic reviews.</p><p class="bulletIndent1"><span class="glyph">●</span>Regional lymph nodes (see  <a class="medical medical_review" href="/d/html/7616.html" rel="external">"Evaluation and management of regional nodes in primary cutaneous melanoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local recurrences (see  <a class="medical medical_review" href="/d/html/7607.html" rel="external">"Cutaneous melanoma: Management of local recurrence"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In-transit metastases (see  <a class="medical medical_review" href="/d/html/7608.html" rel="external">"Cutaneous melanoma: In-transit metastases"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distant metastatic disease (see  <a class="medical medical_review" href="/d/html/131562.html" rel="external">"Metastatic melanoma: Surgical management"</a>)</p><p></p><p class="headingAnchor" id="H416835381"><span class="h1">MELANOMA OF THE TRUNK OR EXTREMITIES</span></p><p class="headingAnchor" id="H1701593750"><span class="h2">Wide excision</span><span class="headingEndMark"> — </span>The initial diagnosis of cutaneous melanoma should be made by biopsy. The approach to biopsy of the suspicious lesion is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Biopsy'</a>.) </p><p>Based on the biopsy result, primary cutaneous melanomas are clinically staged according to their pathologic features (Breslow thickness, presence or absence of ulceration) and whether there is clinical evidence on preoperative physical examination and imaging of regional nodal basin involvement; satellite or in-transit metastases; or distant metastases  (<a class="graphic graphic_table graphicRef110663" href="/d/graphic/110663.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef110664" href="/d/graphic/110664.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"</a>.)</p><p>The thickness of the melanoma is a key factor in determining the clinical stage of the lesion and the recommended margin of normal tissue when resecting the primary tumor. (See <a class="local">'Resection margins'</a> below and  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p>Most wide excisions are performed using an elliptical incision, with the required margin measured in the short axis of the ellipse. The use of an elliptical incision facilitates a generally linear closure along the lines of natural tension, while minimizing standing cones ("dog ears") that may be cosmetically unpleasing. Closure may sometimes be facilitated by curving the ends of the ellipse in a sigmoidal or "hurricane-style" fashion. The specimen should be oriented for the pathologist. It is important to note that the data supporting various margin widths are based on studies in which the surgical margin was measured by the surgeon at the time of resection around the biopsy site and/or residual intact component in situ (ie, a surgical margin) rather than by the pathologist after wide excision has been performed (ie, histologic margin). Due to the elasticity of the skin, compared with the dimensions marked by the surgeon, the skin specimen will almost always shrink in size (hence gross pathologic measurements are often less than measured surgical dimensions); the wide excision field defect will generally expand once the specimen has been removed. (See <a class="local">'Resection margins'</a> below.)</p><p>Wide excision is generally performed down to, but not including, the muscle fascia. Routine inclusion of the muscle fascia during wide excision of cutaneous melanomas of the extremities or trunk does not appear to offer any benefit in terms of long-term local disease control and is not recommended except in uncommon scenarios when it might be necessary to clear a deep margin for an extensive primary melanoma, and/or the fascia was previously disrupted during the initial biopsy procedure. A retrospective review of 964 cases of melanoma ≥1 mm thick included 278 patients (29 percent) who underwent resection of the muscle fascia [<a href="#rid1">1</a>]. There was no decrease in the rate of local recurrence when the muscle fascia was resected. Resection of the fascia was associated with an increase in the incidence of in-transit and regional lymph node metastases. Whether this reflects an effect on the barrier to lymphatic spread or patient selection bias is unknown.</p><p class="headingAnchor" id="H850538405"><span class="h3">Resection margins</span><span class="headingEndMark"> — </span>The recommended width of radial resection margin of normal tissue around a primary cutaneous melanoma lesion is extrapolated from, and based upon, several large clinical trials that examined the impact of the surgical margin on local recurrence rates  (<a class="graphic graphic_table graphicRef73371" href="/d/graphic/73371.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef132563" href="/d/graphic/132563.html" rel="external">table 4</a>) [<a href="#rid2">2-11</a>]. The depth of resection margin was not formally explored in these clinical trials, nor did patients enrolled undergo sentinel lymph node biopsy (SLNB), as it was not standard of care at the time these trials were conducted. Of note, these clinical trials were also conducted prior to the era of systemic and adjuvant immunotherapy and targeted therapy, which can have major impacts on overall and relapse-free survival. </p><p>It is also worth noting that the optimal extent of wide excision for primary cutaneous melanoma remains a subject of investigation, with at least one clinical trial underway. This trial randomizes patients with primary cutaneous melanoma &gt;1 mm Breslow thickness to wide excision with either a 1 cm excision margin or a 2 cm excision margin [<a href="#rid12">12,13</a>]. Outcome measures of this study are local recurrence and melanoma-specific survival. In select cases, reconstruction of the surgical site may be delayed pending "rush" permanent histopathology, since frozen section intraoperative assessment is not generally indicated for margin assessment of primary melanocytic lesions [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1443876106"><span class="h4">Melanoma in situ: 0.5 to 1 cm margin</span><span class="headingEndMark"> — </span>For patients with melanoma in situ (Tis), there are no data from randomized trials to define the optimal extent of surgical resection. We agree with guidelines from the National Comprehensive Cancer Network (NCCN) and the American Academy of Dermatology (AAD) that recommend a margin of 0.5 to 1 cm [<a href="#rid3">3,11,15,16</a>]. We most commonly use a 0.5 cm margin for melanoma in situ followed by evaluation of the histopathology to ensure clearance.</p><p>If the margin is inadequate, additional excision can be performed; however, this is not required for the most of these lesions. Surgeons may sometimes select a 1 cm margin rather than 0.5 cm for melanoma in situ for large and/or ill-defined lesions in which it is difficult to discern the gross extent of the lesion or when there is concern for possible occult invasive melanoma.</p><p class="headingAnchor" id="H3422892528"><span class="h4">T1 melanoma: 1 cm margin</span><span class="headingEndMark"> — </span>For melanomas ≤1 mm thick (T1), we agree with the NCCN and AAD guidelines that recommend a surgical excision margin of 1 cm [<a href="#rid3">3,11</a>]. The original data supporting this approach are from several large trials that showed a low recurrence rate for a 1 cm margin in patients with T1 melanoma [<a href="#rid4">4-6,17,18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a World Health Organization (WHO) trial, 612 patients with melanomas &lt;2 mm thick were randomly assigned to wide excision with a 3 cm margin or with a 1 cm margin [<a href="#rid4">4,17,18</a>]. At 12-year follow-up, survival rates were similar (87 versus 85 percent). The local recurrence rate was 1.8 percent overall and similar between the groups. The four local recurrences that occurred were in patients with primary melanoma &gt;1 mm thick in the 1 cm margin group; there were none in the 3 cm margin group. Based upon these results, a 1 cm margin was recommended for patients with melanoma ≤1 mm thick, but no recommendation was made for thicker melanomas. However, in a subsequent report with additional follow-up, the 3 cm margin group had a local recurrence rate of 1 percent [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial conducted by the Swedish Melanoma Study Group, 989 patients with melanomas 0.8 to 2 mm thick were randomly assigned to 2 or 5 cm resection margins [<a href="#rid5">5</a>]. At a median follow-up of 11 years, the rate of local recurrence for all patients was less than 1 percent and was similar in both groups. There were no differences between the groups in overall or disease-free survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third trial sponsored by the French Cooperative Group consisted of 362 patients with melanomas ≤2 mm in thickness who were randomly assigned to 2 versus 5 cm margins [<a href="#rid6">6</a>]. There was no difference between the groups in the risk of local recurrence or in overall survival.</p><p></p><p>Local recurrence following resection of T1 melanoma is overall low; in a case-control study, it occurred at a median time of 37 months and was associated with narrower excision margins (&lt;8 mm histologic excision margin corresponding to &lt;1 cm surgical margin), as well as other histologic features (desmoplastic, acral, lentigo maligna melanoma subtypes, melanomas composed predominantly of spindle cells) [<a href="#rid15">15,19</a>].</p><p class="headingAnchor" id="H4"><span class="h4">T2 melanoma: 1 to 2 cm margin</span><span class="headingEndMark"> — </span>For melanomas &gt;1 to 2 mm thick (T2), we agree with the NCCN and AAD guidelines that recommend a 1 to 2 cm margin, depending on anatomic constraints based upon the location of the primary melanoma [<a href="#rid3">3,20</a>]. </p><p>In the studies described above (see <a class="local">'T1 melanoma: 1 cm margin'</a> above), outcomes were similar for 2 versus 5 cm margins, and 1 cm margin was similar to 3 cm margin [<a href="#rid4">4-6,17,18</a>]. In the original WHO study, the wider margin (3 cm) for 1 to 2 mm lesions was associated with zero local recurrence, a rate lower (but not significantly lower) than the narrower 1 cm margin. At later follow-up, local recurrence was low in both arms (not zero), but not significantly different between the groups, suggesting that the narrower 1 cm margin is adequate. Thus, when anatomically constrained, a margin of at least 1 cm can be used. </p><p class="headingAnchor" id="H122129038"><span class="h4">T3/T4 melanoma: 2 cm margin</span><span class="headingEndMark"> — </span>For melanomas &gt;2 mm thick, we agree with the NCCN and AAD guidelines that recommend a 2 cm margin. Clinical trials have not demonstrated any benefit for excision margins &gt;2 cm. Clinical trial data supporting this approach include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter European trial (53 sites in Denmark, Sweden, Norway, and Estonia) that enrolled patients from 1992 to 2004, 936 patients with a melanoma on the trunk or extremity greater than 2 mm thick were randomly assigned to either a 2 or 4 cm resection margin [<a href="#rid7">7</a>]. Data regarding use of systemic therapy were not provided, allowing an analysis of the effect of surgery alone (routine use of effective therapy for stage III disease was not practiced at the time of this study). The study may have been underpowered due to slow accrual. Melanoma-specific survival with longer-term follow-up was similar comparing the 2 and 4 cm margin groups (median 19.6 years; hazard ratio [HR] 0.98, 95% CI 0.83-1.14) [<a href="#rid8">8</a>]. There were also no statistically significant differences in overall survival or recurrence-free survival (median follow-up 6.7 years). On multivariate analysis, the highest risk of death was associated with a combination of male sex, age &gt;60 years, thickness &gt;3 mm, location on the trunk, and ulcerated melanoma. Adjustment for prognostic factors did not show any significant effect for width of the resection margin. Local recurrence and recurrence-free survival were not assessed in the longer term. The 19.6-year follow-up was remarkable and notable since only two patients were lost to follow-up at 5.7 and 8.7 years. The study included 53 hospitals from four countries, supporting generalizability of the results. Also remarkable was that all patients were treated per protocol. These long-term data confirmed the short-term mortality results of this trial, as well as data from other mid- to long-term data sets. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Melanoma Intergroup Trial randomly assigned 468 patients with intermediate thickness (1 to 4 mm) melanomas to 2 or 4 cm excision margins [<a href="#rid9">9,21,22</a>]. At a median follow-up of eight years, overall survival and local recurrence-free survival rates were similar for the 2 cm compared with 4 cm excision margin (80 versus 84 percent, respectively, and 0.8 versus 1.7 percent, respectively). On multivariate analysis, independent predictors of local recurrence included tumor thickness and ulceration, but not the excision margin. Patients treated with the 2 cm excision margin had a shorter hospital stay and required skin grafting less frequently (11 versus 46 percent). </p><p></p><p>For melanomas thicker than 4 mm, survival and local recurrence outcomes depend upon the presence of regional and/or distant disease. </p><p class="bulletIndent1"><span class="glyph">●</span>In the European trial of 936 patients, 470 patients had melanoma &gt;3 mm (233 in the 2 cm excision margin group and 241 in the 4 cm excision margin group) [<a href="#rid8">8</a>]. Adjustment for prognostic factors including thickness &gt;3 mm did not change the risk of death for the 2 cm excision margin compared with 4 cm excision margin [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the British trial involving 900 patients, 243 patients (27 percent) had lesions &gt;4 mm thick [<a href="#rid10">10</a>]. Overall, that trial observed an increased risk of local recurrence with 1 cm surgical margins compared with 3 cm (HR 1.26), but with a similar overall survival rate. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The only other series of data for patients with thick (≥4 mm) primary melanomas comes from a retrospective review of 278 patients with a median tumor thickness of 6 mm [<a href="#rid23">23</a>]. There was no correlation between the width of resection (&gt;2 cm versus &lt;2 cm) and local recurrence or overall survival.</p><p></p><p class="headingAnchor" id="H3186315161"><span class="h1">MELANOMA OF OTHER SITES</span></p><p class="headingAnchor" id="H11"><span class="h2">Head and neck</span><span class="headingEndMark"> — </span>The skin of the head and neck accounts for 15 to 25 percent of all primary melanomas, even though this region accounts for about 9 percent of the total surface area of the body [<a href="#rid24">24-27</a>]. Multiple factors may contribute to this anatomic predilection, including higher levels of sun exposure and a melanocyte content of the skin that is two- to threefold higher than other regions. The literature is divided regarding the disease specific outcomes of head and neck melanoma compared with other anatomic sites [<a href="#rid25">25,28-32</a>]. (See  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors"</a>.)</p><p>The recommendations for surgical margins during wide excision of head and neck melanomas are the same as for other cutaneous melanomas (see <a class="local">'Resection margins'</a> above). However, these recommendations were derived from trials in which most patients had melanomas of the trunk or extremities. In the head and neck, such margins are not always attainable and may result in functional disability. Skin grafts are generally avoided whenever possible on the face, but the appropriate excision margins for the extent of tumor thickness should not be compromised solely because of cosmetic factors [<a href="#rid33">33,34</a>]. Flap reconstruction may be required and can often be accomplished with excellent cosmetic results. (See  <a class="medical medical_review" href="/d/html/114188.html" rel="external">"Overview of flaps for soft tissue reconstruction"</a>.)</p><p>It is notable that melanoma in situ lesions on the face, particularly lentigo maligna type, may have indistinct borders and more lateral spread compared with lesions in other locations. For these lesions, Mohs micrographic surgery (MMS) is sometimes used; in selected series, the local recurrence rates and survival have been reported to be similar to wide excision [<a href="#rid16">16,35-39</a>]. However, it is important to note that MMS is not considered the standard of care for invasive melanoma (ie, T1 to T4). (See  <a class="medical medical_review" href="/d/html/13708.html" rel="external">"Mohs surgery", section on 'Specific indications'</a>.)</p><p class="headingAnchor" id="H2111852492"><span class="h2">Other sites</span><span class="headingEndMark"> — </span>Although melanomas are most frequent in sun-exposed areas of the skin (ie, cutaneous melanoma of the trunk, extremities, head/neck), melanoma may arise at other sites, such as in the nail bed, palms, or soles (acral/lentiginous melanoma), on the external genitalia, in mucous membranes (mucosal melanomas), or in the eye (uveal melanoma). These melanomas differ in their epidemiology even though they have a shared cellular origin with the more common cutaneous melanomas [<a href="#rid40">40,41</a>]. While cutaneous and ocular melanomas share a common environmental risk factor (ultraviolet radiation), this may not be the case for all mucosal melanomas [<a href="#rid42">42,43</a>]. </p><p>Early diagnosis facilitates proper treatment and improves survival for patients with these unusual variants. No prospective trials have been undertaken to determine the optimal margins for mucosal, ocular, or acral lentiginous melanomas. The rarity of these melanomas has precluded randomized trials upon which to base treatment decisions, and these rare tumors have generally not been a substantial component of trials designed to determine optimal excision margins. (See <a class="local">'Resection margins'</a> above.)</p><p class="headingAnchor" id="H17"><span class="h3">Acral melanoma</span><span class="headingEndMark"> — </span>Acral melanomas, which occur on subungual sites and the palms and soles, are usually lentiginous [<a href="#rid44">44,45</a>]. In one series, 28 percent of these lesions were unpigmented [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Acral lentiginous melanoma'</a>.)</p><p>Guidelines for cutaneous melanoma excision margins should be followed and preservation of function maximized when possible and oncologically appropriate. (See <a class="local">'Resection margins'</a> above.). </p><p>From an oncologic perspective, it is not generally necessary to resect bone. However, because wide excision of subungual or distal digit invasive melanoma usually yields insufficient soft tissue to maintain a functional digit, partial phalanx bony resection is commonly required. Phalanx-preserving approaches may sometimes be used for subungual or distal digital melanoma in situ. In this clinical scenario, skin grafts or other reconstructive options can be used. For proximal digit and/or web-space-based invasive melanomas, wide excision with preservation of underlying tendonous and bony structure can often be achieved followed by reconstruction of the wide excision site with a skin graft, in contrast to the common need for partial amputation to accompany the wide excision for distal digit invasive melanoma.</p><p>In some series, patients with acral melanomas have a worse prognosis compared with patients who have cutaneous melanomas of the extremities of the same tumor, node, and metastasis (TNM) stage, possibly due to a more aggressive biological course [<a href="#rid47">47-51</a>]. In a multivariate analysis of a single-institution series that included 281 patients with acral melanoma and 843 matched controls, ulceration of the primary tumor and a positive sentinel lymph node biopsy were independently associated with a significantly shorter disease-specific survival. (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a> and  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H18"><span class="h4">Subungual</span><span class="headingEndMark"> — </span>Subungual melanoma arises from the nail matrix and accounts for 0.7 to 3.5 percent of all cases of melanomas [<a href="#rid52">52-54</a>]. The presentation and diagnostic approach to patients with subungual melanoma are discussed separately (see  <a class="medical medical_review" href="/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Melanoma'</a>). </p><p>Guidelines for cutaneous melanoma excision margins should be followed and preservation of function maximized when possible and oncologically appropriate. (See <a class="local">'Resection margins'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Subungual melanomas involving the toes can generally be managed with digital amputation at the interphalangeal or metatarsal-phalangeal joint depending on location and local extent of disease, although phalanx-preserving approaches may sometimes be used for subungual melanoma in situ. </p><p></p><p class="bulletIndent1">Postoperative consultation to fit appropriate shoes/orthotics is appropriate. (See  <a class="medical medical_review" href="/d/html/15186.html" rel="external">"Techniques for lower extremity amputation", section on 'Foot amputations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whenever possible, subungual melanomas of the fingers should be resected at the distal interphalangeal joint to preserve function [<a href="#rid55">55</a>]. Proximally located cutaneous melanomas on the fingers can often be managed with excision (as with other cutaneous melanomas) and without bony resection; in such situations, reconstruction can often be achieved by skin graft or possibly a local flap for soft tissue coverage. (See  <a class="medical medical_review" href="/d/html/15224.html" rel="external">"Upper extremity amputation", section on 'Digit and thumb amputation'</a> and  <a class="medical medical_review" href="/d/html/16527.html" rel="external">"Surgical reconstruction of the upper extremity"</a>.)</p><p></p><p>As with other melanomas, increasing tumor thickness and the presence of ulceration in the tumor are associated with a worse prognosis [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H19"><span class="h4">Plantar/palmar</span><span class="headingEndMark"> — </span>For melanomas arising on the sole of the foot or the palm of the hand, excisions are almost never closed, primarily due to the lack of surplus skin. Skin grafts can be performed, but some weight-bearing areas may require more substantial soft tissue coverage. One approach is to allow the excision wound to granulate before skin grafting, either through dressing changes or with negative pressure wound therapy. Alternatively, rotation, advancement, or free flaps may be used. (See  <a class="medical medical_review" href="/d/html/2881.html" rel="external">"Negative pressure wound therapy"</a> and  <a class="medical medical_review" href="/d/html/114188.html" rel="external">"Overview of flaps for soft tissue reconstruction"</a> and  <a class="medical medical_review" href="/d/html/16527.html" rel="external">"Surgical reconstruction of the upper extremity"</a> and  <a class="medical medical_review" href="/d/html/15121.html" rel="external">"Surgical reconstruction of the lower extremity"</a>.)</p><p>The prognosis for patients with plantar melanoma is worse compared with that for patients with melanomas of the lower extremity of comparable thickness [<a href="#rid49">49-51</a>]. This was illustrated in a series of 51 patients with plantar melanoma and 239 controls with stage I melanomas of the leg [<a href="#rid57">57</a>]. The five-year disease-free survival rates were significantly worse for patients with plantar melanomas compared with those with primary leg lesions (82 versus 95 percent for lesions &lt;1.5 mm, 51 versus 71 percent for lesions 1.5 to 3.49 mm, and 46 versus 0 percent for lesions ≥3.5 mm thick). At the author's institution, findings were similar among patients diagnosed and treated for T1 melanoma between 1994 to 2009 [<a href="#rid49">49</a>]. Disease-specific survival was worse among 129 patients with T1 acral lentiginous melanoma compared with 699 patients with T1 non-acral lentiginous melanoma (five-year survival: 90 versus 99 percent, respectively; ten-year survival: 82 versus 98 percent, respectively).</p><p class="headingAnchor" id="H367031380"><span class="h3">Unusual sites</span></p><p class="bulletIndent1"><span class="glyph">●</span>Genital melanoma – Melanoma presenting on the male or female external genitalia is rare and associated with a poor prognosis. These may require gynecologic, urologic, and/or plastic/reconstructive expertise to achieve optimal resection margins while sparing/reconstructing the genitalia, whenever possible. (See  <a class="medical medical_review" href="/d/html/3002.html" rel="external">"Carcinoma of the penis: Epidemiology, risk factors, and pathology", section on 'Melanoma'</a> and  <a class="medical medical_review" href="/d/html/3237.html" rel="external">"Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment", section on 'Melanoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal melanoma – Mucosal melanomas can occur at a variety of sites, including the head and neck (oral cavity, nasal cavity, paranasal sinuses), anorectal region, female genital tract, and urinary tract. Approach towards the resection of these varied lesions depends upon their location. The pathogenesis, presentation, and management of mucosal melanoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/16904.html" rel="external">"Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uveal melanoma – The unique presentation and surgical management of uveal melanoma is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas"</a> and  <a class="medical medical_review" href="/d/html/113047.html" rel="external">"Metastatic uveal melanoma"</a>.) </p><p></p><p class="headingAnchor" id="H3647521356"><span class="h1">DESMOPLASTIC MELANOMA</span><span class="headingEndMark"> — </span>Desmoplastic melanoma is a rare variant that comprises less than 5 percent of melanoma cases [<a href="#rid58">58</a>]. Desmoplastic melanoma is more commonly diagnosed in men with a 2:1 male-to-female ratio. Patients tend to be older at diagnosis (median age 60 to 70 years) compared with patients with non-desmoplastic melanoma (median age approximately 50 years) [<a href="#rid58">58-61</a>]. Pure desmoplastic melanoma is empirically defined by most as &gt;90 percent of the invasive melanoma and associated with prominent stromal fibrosis. Desmoplastic melanoma is more common in the head and neck region than in other areas of the body, with most series reporting 50 percent or more cases in the head and neck location [<a href="#rid58">58,61</a>]. </p><p>Although desmoplastic melanomas may surround or directly invade nerves (a variant known as neurotropic melanoma), in general, the prognosis associated with desmoplastic melanoma appears to be better compared with other cutaneous melanomas of the same stage [<a href="#rid58">58,62-70</a>]. The pathological features of desmoplastic melanoma and correlation with prognostic factors are reviewed separately. (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p>The initial management of patients with desmoplastic melanoma is wide excision with margin based on the thickness of the primary tumor (see <a class="local">'Resection margins'</a> above). Negative margins may sometimes be difficult to obtain but should be sought in all cases; appropriate margin is important for local control, particularly for pure desmoplastic melanoma. Pure desmoplastic melanomas appear to have lower rates of lymph node involvement compared with mixed desmoplastic and non-desmoplastic melanomas (2.2 percent versus 15.8 and 17.5 percent, respectively) [<a href="#rid63">63,71-74</a>]. However, there is variability in reported rate of sentinel lymph node biopsy (SLNB) positivity in desmoplastic melanoma, possibly due to limitations of histopathologic reproducibility or reporting [<a href="#rid75">75,76</a>]. Thus, the role of SLNB for patients with pure desmoplastic melanoma is controversial, unlike for patients with conventional melanoma or mixed desmoplastic melanoma subtypes. </p><p>Following wide excision, adjuvant radiotherapy can be considered with multidisciplinary input in the treatment of primary desmoplastic melanoma to improve local control in patients at high risk of local recurrence, such as in cases in which extensive neurotropism is present or if achievable excision margins are suboptimal [<a href="#rid71">71,77-79</a>]. (See  <a class="medical medical_review" href="/d/html/7614.html" rel="external">"Radiation therapy in the management of melanoma", section on 'Desmoplastic melanoma'</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">ADJUVANT THERAPY AND SURVEILLANCE AFTER SURGERY</span><span class="headingEndMark"> — </span>Adjuvant therapy and surveillance after initial surgical management of primary cutaneous melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma"</a> and  <a class="medical medical_review" href="/d/html/7614.html" rel="external">"Radiation therapy in the management of melanoma"</a> and  <a class="medical medical_review" href="/d/html/7621.html" rel="external">"Staging work-up and surveillance of cutaneous melanoma", section on 'Surveillance'</a>.)</p><p class="headingAnchor" id="H2336871539"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a> and  <a class="medical medical_society_guidelines" href="/d/html/123058.html" rel="external">"Society guideline links: Mohs surgery"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/892.html" rel="external">"Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/889.html" rel="external">"Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melanoma diagnosis</strong> – Biopsy is necessary to establish a diagnosis of melanoma. Once melanoma has been confirmed, wide excision of the primary melanoma site with an appropriate surgical margin of normal tissue based on tumor thickness and anatomic location is necessary for definitive treatment and pathologic staging. When sentinel lymph node biopsy (SLNB) is indicated for surgical staging, wide excision and SLNB should be performed in the same operative setting. (See <a class="local">'Role of surgery'</a> above and  <a class="medical medical_review" href="/d/html/7616.html" rel="external">"Evaluation and management of regional nodes in primary cutaneous melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wide excision</strong> – The recommended width of normal tissue to resect (ie, surgical or resection margin) at the time of definitive surgical treatment for primary cutaneous melanoma of the trunk and extremities is based on the thickness of the primary tumor  (<a class="graphic graphic_table graphicRef110663" href="/d/graphic/110663.html" rel="external">table 1</a>). Note that these margins do not refer to histological margin from the wide excision pathology report. (See <a class="local">'Wide excision'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Margins for cutaneous melanoma</strong> – We agree with guidelines from the National Comprehensive Cancer Network (NCCN) and the American Academy of Dermatology (AAD). For most cutaneous melanomas, we suggest the margins for surgical resection given below, rather than narrower or wider margins (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)<strong> </strong>(see <a class="local">'Resection margins'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For melanoma in situ (Tis)</strong> – A 0.5 to 1 cm surgical resection margin; a 0.5 cm margin is commonly used. No randomized trial data are available to support either a narrower or wider resection. Mohs micrographic surgery may also be appropriate for melanoma in situ, particularly for lentigo maligna type located in the head and neck region, in selected patients. (See <a class="local">'Melanoma in situ: 0.5 to 1 cm margin'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For cutaneous melanomas ≤1 mm thick (T1)</strong> – A 1 cm resection margin. Based on the available clinical trial data, a wider resection does not appear to improve recurrence-free or overall survival. (See <a class="local">'T2 melanoma: 1 to 2 cm margin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For cutaneous melanomas &gt;1 to 2 mm thick (T2)</strong> – A 1 to 2 cm resection margin. Based on the available clinical trial data, a wider resection margin has not improved recurrence-free or overall survival. For T2 melanoma in which a 2 cm margin is anatomically constrained or the 2 cm margin would require a skin graft, a 1 cm margin is acceptable. (See <a class="local">'T2 melanoma: 1 to 2 cm margin'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For cutaneous melanomas &gt;2 mm thick (T3, T4)</strong> – A 2 cm resection margin. Based on the available clinical trial data, a more wider resection margin has improved recurrence-free or overall survival. For T4 melanomas, outcomes depend predominantly upon the presence of regional and/or distant disease. (See <a class="local">'T3/T4 melanoma: 2 cm margin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other melanoma sites</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Head and neck melanoma</strong> – For patients with cutaneous melanoma arising in the skin of the head and neck region, similar principles of wide excision should be applied. Adjuvant radiation therapy may be indicated if the location of the melanoma precludes an adequate resection margin or if the lesion is at particularly high risk of local recurrence (eg, desmoplastic melanoma). (See <a class="local">'Head and neck'</a> above and <a class="local">'Desmoplastic melanoma'</a> above and  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subungual/plantar/palmar sites</strong> – For patients with melanomas arising in subungual or plantar/palmar sites or on mucous membranes, similar principles of wide excision should be applied, but these sites may require specific resections depending upon the anatomic location and restraints. Wide resection &gt;1 cm may preclude primary closure, and skin grafts or reconstructive techniques are often required for wound coverage. (See <a class="local">'Acral melanoma'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Grotz TE, Glorioso JM, Pockaj BA, et al. Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery 2013; 153:535.</a></li><li><a class="nounderline abstract_t">Wheatley K, Wilson JS, Gaunt P, Marsden JR. Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation. Cancer Treat Rev 2016; 42:73.</a></li><li><a class="nounderline abstract_t">Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019; 80:208.</a></li><li><a class="nounderline abstract_t">Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998; 14:272.</a></li><li><a class="nounderline abstract_t">Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89:1495.</a></li><li><a class="nounderline abstract_t">Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97:1941.</a></li><li><a class="nounderline abstract_t">Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011; 378:1635.</a></li><li><a class="nounderline abstract_t">Utjés D, Malmstedt J, Teras J, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. Lancet 2019; 394:471.</a></li><li><a class="nounderline abstract_t">Karakousis CP, Balch CM, Urist MM, et al. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3:446.</a></li><li><a class="nounderline abstract_t">Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350:757.</a></li><li><a class="nounderline abstract_t">Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 2021; 19:364.</a></li><li><a class="nounderline abstract_t">Coit D, Ariyan C. MelMART Trial: It's Now or Never. Ann Surg Oncol 2018; 25:2493.</a></li><li class="breakAll">Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma https://clinicaltrials.gov/ct2/show/NCT02385214 (Accessed on August 10, 2021).</li><li><a class="nounderline abstract_t">Prieto VG, Argenyi ZB, Barnhill RL, et al. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol 2003; 120:203.</a></li><li><a class="nounderline abstract_t">Kunishige JH, Doan L, Brodland DG, Zitelli JA. Comparison of surgical margins for lentigo maligna versus melanoma in situ. J Am Acad Dermatol 2019; 81:204.</a></li><li><a class="nounderline abstract_t">Valentín-Nogueras SM, Brodland DG, Zitelli JA, et al. Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ. Dermatol Surg 2016; 42:733.</a></li><li><a class="nounderline abstract_t">Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318:1159.</a></li><li><a class="nounderline abstract_t">Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126:438.</a></li><li><a class="nounderline abstract_t">MacKenzie Ross AD, Haydu LE, Quinn MJ, et al. The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study. Ann Surg Oncol 2016; 23:1082.</a></li><li><a class="nounderline abstract_t">Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011; 65:1032.</a></li><li><a class="nounderline abstract_t">Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218:262.</a></li><li><a class="nounderline abstract_t">Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7:87.</a></li><li><a class="nounderline abstract_t">Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (&gt;4mm) primary melanoma. Ann Surg Oncol 1998; 5:322.</a></li><li><a class="nounderline abstract_t">Gibbs P, Robinson WA, Pearlman N, et al. Management of primary cutaneous melanoma of the head and neck: The University of Colorado experience and a review of the literature. J Surg Oncol 2001; 77:179.</a></li><li><a class="nounderline abstract_t">Golger A, Young DS, Ghazarian D, Neligan PC. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg 2007; 133:442.</a></li><li><a class="nounderline abstract_t">Goepfert RP, Myers JN, Gershenwald JE. Updates in the evidence-based management of cutaneous melanoma. Head Neck 2020; 42:3396.</a></li><li><a class="nounderline abstract_t">Gillgren P, Månsson-Brahme E, Frisell J, et al. A prospective population-based study of cutaneous malignant melanoma of the head and neck. Laryngoscope 2000; 110:1498.</a></li><li><a class="nounderline abstract_t">Lentsch EJ, Myers JN. Melanoma of the head and neck: current concepts in diagnosis and management. Laryngoscope 2001; 111:1209.</a></li><li><a class="nounderline abstract_t">Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol 2008; 144:515.</a></li><li><a class="nounderline abstract_t">Tseng WH, Martinez SR. Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res 2011; 167:192.</a></li><li><a class="nounderline abstract_t">Rohde M, Fürstenau U, Mayer F, et al. Localization of membrane-associated (NiFe) and (NiFeSe) hydrogenases of Desulfovibrio vulgaris using immunoelectron microscopic procedures. Eur J Biochem 1990; 191:389.</a></li><li><a class="nounderline abstract_t">Helsing P, Robsahm TE, Vos L, et al. Cutaneous head and neck melanoma (CHNM): A population-based study of the prognostic impact of tumor location. J Am Acad Dermatol 2016; 75:975.</a></li><li><a class="nounderline abstract_t">Glat PM, Longaker MT, Jelks EB, et al. Periorbital melanocytic lesions: excision and reconstruction in 40 patients. Plast Reconstr Surg 1998; 102:19.</a></li><li><a class="nounderline abstract_t">Hudson DA, Krige JE, Grobbelaar AO, et al. Melanoma of the face: the safety of narrow excision margins. Scand J Plast Reconstr Surg Hand Surg 1998; 32:97.</a></li><li><a class="nounderline abstract_t">Nosrati A, Berliner JG, Goel S, et al. Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision. JAMA Dermatol 2017; 153:436.</a></li><li><a class="nounderline abstract_t">Phan K, Loya A. Mohs micrographic surgery versus wide local excision for melanoma in situ: analysis of a nationwide database. Int J Dermatol 2019; 58:697.</a></li><li><a class="nounderline abstract_t">Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol 2012; 66:438.</a></li><li><a class="nounderline abstract_t">Akhtar S, Bhat W, Magdum A, Stanley PR. Surgical excision margins for melanoma in situ. J Plast Reconstr Aesthet Surg 2014; 67:320.</a></li><li><a class="nounderline abstract_t">Ad Hoc Task Force, Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 2012; 67:531.</a></li><li><a class="nounderline abstract_t">Merkel EA, Gerami P. Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features. Lab Invest 2017; 97:630.</a></li><li><a class="nounderline abstract_t">Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature 2017; 545:175.</a></li><li><a class="nounderline abstract_t">McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005; 103:1000.</a></li><li><a class="nounderline abstract_t">Chiu NT, Weinstock MA. Melanoma of oronasal mucosa. Population-based analysis of occurrence and mortality. Arch Otolaryngol Head Neck Surg 1996; 122:985.</a></li><li><a class="nounderline abstract_t">Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol 2000; 143:275.</a></li><li><a class="nounderline abstract_t">Slingluff CL Jr, Vollmer R, Seigler HF. Acral melanoma: a review of 185 patients with identification of prognostic variables. J Surg Oncol 1990; 45:91.</a></li><li><a class="nounderline abstract_t">Phan A, Touzet S, Dalle S, et al. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol 2006; 155:561.</a></li><li><a class="nounderline abstract_t">Bello DM, Chou JF, Panageas KS, et al. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol 2013; 20:3618.</a></li><li><a class="nounderline abstract_t">Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 2009; 145:427.</a></li><li><a class="nounderline abstract_t">Mejbel HA, Torres-Cabala CA, Milton DR, et al. Prognostic significance of acral lentiginous histologic type in T1 melanoma. Mod Pathol 2021; 34:572.</a></li><li><a class="nounderline abstract_t">Huang K, Fan J, Misra S. Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry. J Surg Res 2020; 251:329.</a></li><li><a class="nounderline abstract_t">Behbahani S, Malerba S, Samie FH. Acral lentiginous melanoma: clinicopathological characteristics and survival outcomes in the US National Cancer Database 2004-2016. Br J Dermatol 2020; 183:952.</a></li><li><a class="nounderline abstract_t">Littleton TW, Murray PM, Baratz ME. Subungual Melanoma. Orthop Clin North Am 2019; 50:357.</a></li><li><a class="nounderline abstract_t">Levit EK, Kagen MH, Scher RK, et al. The ABC rule for clinical detection of subungual melanoma. J Am Acad Dermatol 2000; 42:269.</a></li><li><a class="nounderline abstract_t">Park KG, Blessing K, Kernohan NM. Surgical aspects of subungual malignant melanomas. The Scottish Melanoma Group. Ann Surg 1992; 216:692.</a></li><li><a class="nounderline abstract_t">Heaton KM, el-Naggar A, Ensign LG, et al. Surgical management and prognostic factors in patients with subungual melanoma. Ann Surg 1994; 219:197.</a></li><li><a class="nounderline abstract_t">Finley RK 3rd, Driscoll DL, Blumenson LE, Karakousis CP. Subungual melanoma: an eighteen-year review. Surgery 1994; 116:96.</a></li><li><a class="nounderline abstract_t">Dwyer PK, Mackie RM, Watt DC, Aitchison TC. Plantar malignant melanoma in a white Caucasian population. Br J Dermatol 1993; 128:115.</a></li><li><a class="nounderline abstract_t">Nicolson NG, Han D. Desmoplastic melanoma. J Surg Oncol 2019; 119:208.</a></li><li><a class="nounderline abstract_t">Xu Z, Yibulayin F, Shi P, Feng L. Desmoplastic melanoma versus spindle cell melanoma: Incidence and survival, 1973 to 2017. Medicine (Baltimore) 2018; 97:e11563.</a></li><li><a class="nounderline abstract_t">Feng Z, Wu X, Chen V, et al. Incidence and survival of desmoplastic melanoma in the United States, 1992-2007. J Cutan Pathol 2011; 38:616.</a></li><li><a class="nounderline abstract_t">Hughes TM, Williams GJ, Gyorki DE, et al. Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. J Eur Acad Dermatol Venereol 2021; 35:1290.</a></li><li><a class="nounderline abstract_t">Murali R, Shaw HM, Lai K, et al. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer 2010; 116:4130.</a></li><li><a class="nounderline abstract_t">Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 2006; 106:900.</a></li><li><a class="nounderline abstract_t">Livestro DP, Muzikansky A, Kaine EM, et al. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol 2005; 23:6739.</a></li><li><a class="nounderline abstract_t">Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998; 83:1128.</a></li><li><a class="nounderline abstract_t">Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 2005; 12:207.</a></li><li><a class="nounderline abstract_t">Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol 2005; 152:673.</a></li><li><a class="nounderline abstract_t">Posther KE, Selim MA, Mosca PJ, et al. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol 2006; 13:728.</a></li><li><a class="nounderline abstract_t">Chen JY, Hruby G, Scolyer RA, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008; 113:2770.</a></li><li><a class="nounderline abstract_t">Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol 1995; 32:717.</a></li><li><a class="nounderline abstract_t">Varey AHR, Goumas C, Hong AM, et al. Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Mod Pathol 2017; 30:1538.</a></li><li><a class="nounderline abstract_t">Murali R, Shaw HM, Lai K, et al. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer 2010; 116:4130.</a></li><li><a class="nounderline abstract_t">Gyorki DE, Busam K, Panageas K, et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol 2003; 10:403.</a></li><li><a class="nounderline abstract_t">Eppsteiner RW, Swick BL, Milhem MM, et al. Sentinel node biopsy for head and neck desmoplastic melanoma: not a given. Otolaryngol Head Neck Surg 2012; 147:271.</a></li><li><a class="nounderline abstract_t">Han D, Zager JS, Yu D, et al. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? Ann Surg Oncol 2013; 20:2345.</a></li><li><a class="nounderline abstract_t">Broer PN, Walker ME, Goldberg C, et al. Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy. Eur J Surg Oncol 2013; 39:681.</a></li><li><a class="nounderline abstract_t">Guadagnolo BA, Prieto V, Weber R, et al. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. Cancer 2014; 120:1361.</a></li><li><a class="nounderline abstract_t">Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer 2014; 120:1369.</a></li><li><a class="nounderline abstract_t">Rule WG, Allred JB, Pockaj BA, et al. Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. Cancer Med 2016; 5:1890.</a></li></ol></div><div id="topicVersionRevision">Topic 7620 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218886" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Preservation of the deep muscular fascia and locoregional control in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563920" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30392755" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guidelines of care for the management of primary cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588719" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Margin of resection in the management of primary melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013363" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12673721" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22027547" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31280965" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876886" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14973217" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Excision margins in high-risk malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33845460" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : NCCN Guidelines®Insights: Melanoma: Cutaneous, Version 2.2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946999" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : MelMART Trial: It's Now or Never.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946999" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : MelMART Trial: It's Now or Never.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12931550" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31014825" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of surgical margins for lentigo maligna versus melanoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27158886" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3079582" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2009058" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26561405" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868127" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8373269" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10761786" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9641453" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Surgical margins and prognostic factors in patients with thick (&gt;4mm) primary melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11455554" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of primary cutaneous melanoma of the head and neck: The University of Colorado experience and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515502" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33463835" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Updates in the evidence-based management of cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10983950" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A prospective population-based study of cutaneous malignant melanoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11568543" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Melanoma of the head and neck: current concepts in diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18427046" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21176922" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tumor location predicts survival in cutaneous head and neck melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1696542" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Localization of membrane-associated (NiFe) and (NiFeSe) hydrogenases of Desulfovibrio vulgaris using immunoelectron microscopic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27546291" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cutaneous head and neck melanoma (CHNM): A population-based study of the prognostic impact of tumor location.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655402" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Periorbital melanocytic lesions: excision and reconstruction in 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9556824" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Melanoma of the face: the safety of narrow excision margins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241261" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30604517" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mohs micrographic surgery versus wide local excision for melanoma in situ: analysis of a nationwide database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22196979" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Surgical margins for melanoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24444795" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Surgical excision margins for melanoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22959232" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28092366" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28467829" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Whole-genome landscapes of major melanoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15651058" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Incidence of noncutaneous melanomas in the U.S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797564" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Melanoma of oronasal mucosa. Population-based analysis of occurrence and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10951133" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2214797" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acral melanoma: a review of 185 patients with identification of prognostic variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16911282" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acral lentiginous melanoma: a clinicoprognostic study of 126 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23838913" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prognosis of acral melanoma: a series of 281 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380664" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32759976" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prognostic significance of acral lentiginous histologic type in T1 melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32208196" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407556" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Acral lentiginous melanoma: clinicopathological characteristics and survival outcomes in the US National Cancer Database 2004-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31084838" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Subungual Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10642684" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The ABC rule for clinical detection of subungual melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1466623" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Surgical aspects of subungual malignant melanomas. The Scottish Melanoma Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129491" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Surgical management and prognostic factors in patients with subungual melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023276" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Subungual melanoma: an eighteen-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8457443" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Plantar malignant melanoma in a white Caucasian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30481377" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Desmoplastic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30024556" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Desmoplastic melanoma versus spindle cell melanoma: Incidence and survival, 1973 to 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518379" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Incidence and survival of desmoplastic melanoma in the United States, 1992-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33544941" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564101" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16411225" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170181" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Biology of desmoplastic melanoma: a case-control comparison with other melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740077" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827812" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840097" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Desmoplastic malignant melanoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16538415" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823042" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7722014" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Desmoplastic malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28731051" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564101" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734089" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22399279" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Sentinel node biopsy for head and neck desmoplastic melanoma: not a given.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23389470" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23522951" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142803" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The role of adjuvant radiotherapy in the local management of desmoplastic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142775" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Radiotherapy influences local control in patients with desmoplastic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27368067" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
